Find A Multiple Myeloma Trial
Search for a multiple myeloma clinical trial. You may need to satisfy additional criteria in order to be eligible for a study.
Talk With a Patient Navigator
For additional support click here to get connected with a patient navigator.
Talk With a Patient Navigator
For additional support click here to get connected with a patient navigator.
Multiple Myeloma
Age: 18 +
Genders: All
Phase: Phase 1
The study aims to use T lymphocytes to target tumor associated antigens (TAAs) in patients with Multiple Myeloma, monoclonal gammopathy of undetermined significance (MGUS) or smoldering myeloma (SM). Its purpose is to determine the safety and effectiveness of this experimental therapy, with the goal of arresting the progression of the patient's condition to multiple myeloma.
*Third Opinion AI Generated Synopsis
Plasmacytoma, Recurrent Multiple Myeloma, and Refractory Multiple Myeloma
Age: 18 +
Genders: All
Phase: Phase 1
This trial is testing the safety and best dosage of MDM2 Inhibitor KRT-232 in combination with carfilzomib, lenalidomide, and dexamethasone for patients whose multiple myeloma has returned or not responded to previous treatment. These drugs work in different ways to stop the growth of cancer cells, and the combination may be more effective.
*Third Opinion AI Generated Synopsis
Immune System Diseases and Multiple Myeloma
Age: 18 +
Genders: All
Phase: Phase 1
Researchers are studying a treatment for multiple myeloma that combines antibodies and T cells to create a more effective treatment. The new treatment involves adding a gene to T cells that produces an antibody that detects and sticks to cancer cells called multiple myeloma cells, which directs T cells to fight the cancer.
*Third Opinion AI Generated Synopsis
Recurrent Plasma Cell Myeloma and Refractory Plasma Cell Myeloma
Age: 18 +
Genders: All
Phase: Phase 1
The study is testing the side effects and appropriate dosage of a therapy called CS1-CAR T, which modifies immune cells to kill cancer cells in patients with CS1-positive multiple myeloma that has relapsed or not responded well to previous treatments. CS1-CAR T cells are engineered immune cells that recognize and eliminate cancer cells.
*Third Opinion AI Generated Synopsis
Plasma Cell Myeloma
Age: 18 +
Genders: All
Phase: Phase 3
This trial is testing whether a combination of lenalidomide and ixazomib is more effective than lenalidomide alone in treating multiple myeloma that remains after stem cell transplantation. Both drugs have the potential to slow or stop the growth of cancer cells.
*Third Opinion AI Generated Synopsis
Multiple Myeloma, Multiple Myeloma in Relapse, Refractory Multiple Myeloma, and Relapse
Age: 18 - 80
Genders: All
Phase: Phase 2
The study aims to evaluate the effectiveness of combining daratumumab with weekly carfilzomib, pomalidomide, and dexamethasone in treating people with relapsed and refractory Multiple Myeloma, a condition in which previously treated Multiple Myeloma returns or becomes resistant to treatment.
*Third Opinion AI Generated Synopsis
Plasma Cell Myeloma and Renal Failure
Age: 18 +
Genders: All
Phase: Phase 2
This study evaluates the effectiveness of daratumumab-based therapy in treating patients with newly diagnosed multiple myeloma with kidney failure. The therapy includes daratumumab, bortezomib, dexamethasone, and thalidomide or lenalidomide, all of which may help prevent the growth and spread of cancer cells.
*Third Opinion AI Generated Synopsis
Kahler Disease, Multiple Myeloma, Myeloma Multiple, Myeloma-Multiple, Myeloma, Plasma Cell, Myelomatosis, and Plasma Cell Myeloma
Age: 18 +
Genders: All
Phase: Phase 2
The trial will test the efficacy of using selinexor with daratumumab, lenalidomide, and dexamethasone (DRd) as a first-line treatment for multiple myeloma (MM). Selinexor is already approved by the FDA for use with dexamethasone after several prior therapies, and DRd is also approved for MM.
*Third Opinion AI Generated Synopsis
Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma
Age: 18 +
Genders: All
Phase: Phase 2
The study is examining whether the drug metformin could prevent patients with MGUS and SMM from developing multiple myeloma, using a metformin-extended release medication and a placebo.
*Third Opinion AI Generated Synopsis
Plasma Cell Myeloma
Age: 18 +
Genders: All
Phase: Phase 2
This trial is examining how the combination of belantamab mafodotin and lenalidomide affects patients with multiple myeloma who still have small amounts of cancer after a stem cell transplant. By targeting specific receptors on cancer cells and delivering a chemotherapy drug, belantamab mafodotin may help kill these cells, while lenalidomide may prevent further cancer growth. The goal is to keep the disease at very low levels in patients.
*Third Opinion AI Generated Synopsis
Recurrent Plasma Cell Myeloma and Refractory Plasma Cell Myeloma
Age: 18 - 75
Genders: All
Phase: Phase 1
A phase I trial is testing whether adding panobinostat to a combination of daratumumab, bortezomib, and dexamethasone could benefit patients with relapsed or refractory multiple myeloma by blocking the growth of new blood vessels that are necessary for cancer growth. The study aims to determine if this combination treatment will work better than the current standard treatment for the disease.
*Third Opinion AI Generated Synopsis
Multiple Myeloma
Age: 18 +
Genders: All
Phase: Phase 1
A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Patients With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
Multiple Myeloma
Age: 18 +
Genders: All
Phase: Phase 1
Researchers will test the safety and efficacy of combining TTI-622 and daratumumab hyaluronidase-fihj in people with relapsed/refractory multiple myeloma by finding the highest safe dose of each study drug and then testing the combination in new participants. This combination may be an effective treatment approach for multiple myeloma.
*Third Opinion AI Generated Synopsis
Relapsed/Refractory Multiple Myeloma
Age: 18 +
Genders: All
Phase: Phase 1
The study will assess the safety and toxicity of investigational drug ABBV-383 when given with other medications to adult patients with relapsed/refractory multiple myeloma. The study will include a dose escalation and dose expansion phase, with approximately 270 participants at sites worldwide, and treatment burden may be higher than standard of care.
*Third Opinion AI Generated Synopsis
Plasma Cell Myeloma, Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma, and Smoldering Plasma Cell Myeloma
Age: 18 +
Genders: All
Phase: Phase 2
This trial is testing a combination of immunomodulatory drugs and corticosteroids to treat multiple myeloma or smoldering multiple myeloma. The study aims to identify which drug combinations work best in treating these types of cancer.
*Third Opinion AI Generated Synopsis
High-risk Smoldering Multiple Myeloma, Multiple Myeloma, and Smoldering Multiple Myeloma
Age: 18 +
Genders: All
Phase: Phase 2
This study aims to compare Teclistamab with Lenalidomide + Dexamethasone in individuals with high risk smoldering multiple myeloma to test the anti-cancer activity of Teclistamab. Smoldering multiple myeloma is a condition where individuals are at risk for developing active multiple myeloma and no approved therapies currently exist for it.
*Third Opinion AI Generated Synopsis
Plasma Cell Myeloma
Age: Any Age.
Genders: All
Phase: Phase 3
In a phase III trial, researchers are comparing three different drug combinations for the treatment of newly diagnosed multiple myeloma in patients who are not receiving a stem cell transplant and considered frail or intermediate-fit. The goal is to determine which combination of drugs is more effective in shrinking and controlling the cancer.
*Third Opinion AI Generated Synopsis
Smoldering Multiple Myeloma
Age: 18 +
Genders: All
Phase: Phase 2
Selinexor for the Treatment of Intermediate and High-Risk Smoldering Multiple Myeloma
Multiple Myeloma
Age: 18 +
Genders: All
Phase: Phase 3
A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135), Daratumumab, and Lenalidomide Compared With Daratumumab, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
Multiple Myeloma
Age: 18 +
Genders: All
Phase: Phase 1
This study is testing a new drug, ABBV-383, for the treatment of relapsed/refractory Multiple Myeloma. The study will enroll around 80 adult participants who will receive the drug through an infusion in 28 day cycles for approximately 3 years. Regular visits, medical assessments, blood tests, and questionnaires will be conducted to assess the treatment's effectiveness and any side effects.
*Third Opinion AI Generated Synopsis
Multiple Myeloma and Plasma Cell Myeloma
Age: 18 +
Genders: All
Phase: Phase 1
This trial is evaluating the safety and efficacy of [89Zr]DFO-YS5 PET imaging in detecting CD46 positive cancer cells in patients with multiple myeloma. [89Zr]DFO-YS5 is a radiopharmaceutical tracer that targets CD46 and may enhance the detection of multiple myeloma.
*Third Opinion AI Generated Synopsis
Multiple Myeloma
Age: 18 +
Genders: All
Phase: Phase 1
Mezigdomide (CC-92480) Post Idecabtagene Vicleucel in Treating Patients With Relapsed Multiple Myeloma
Multiple Myeloma
Age: 18 +
Genders: All
Phase: Phase 1
A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30)
Multiple Myeloma
Age: 18 +
Genders: All
Phase: Phase 2
Researchers are conducting a study to test a combination drug treatment called DKd on people who have smoldering multiple myeloma, which could help prevent or slow down the progression of the disease before organ damage occurs. Participants will receive the treatments in 28-day cycles and will have regular study visits, follow-up appointments, and may have stem cells collected.
*Third Opinion AI Generated Synopsis
Multiple Myeloma
Age: 18 +
Genders: All
Phase: Phase 2
A study will be conducted to evaluate the efficacy and safety of bb2121 in subjects with multiple myeloma who have relapsed, progressed within a certain time frame, or have had an inadequate response to prior treatments. The study will enroll approximately 235 subjects across three cohorts, and will also include newly diagnosed multiple myeloma participants with suboptimal response to autologous stem cell transplantation.
*Third Opinion AI Generated Synopsis
Multiple Myeloma
Age: Any Age.
Genders: All
Phase: Phase 3
This study aims to give continuous access to treatment for participants with multiple myeloma or smoldering multiple myeloma who have benefited from daratumumab studies. It will also collect long-term safety data from the participants.
*Third Opinion AI Generated Synopsis
Multiple Myeloma
Age: 18 +
Genders: All
Phase: Phase 1
Multiple myeloma patients will receive an investigational cancer vaccine called TXSVN, derived from a weakened form of the Salmonella bacteria that has been genetically modified in the laboratory to produce a protein known as Survivin. The vaccine aims to activate the immune system and develop a response against cancer cells that contain Survivin, with the aim of finding a safe dose, monitoring side effects, and assessing any potential benefits of the therapy.
*Third Opinion AI Generated Synopsis
Multiple Myeloma
Age: 18 +
Genders: All
Phase: Phase 3
This study aims to determine if the combination of the BCMA-CD3 bispecific antibody elranatamab with daratumumab can provide better outcomes for people with multiple myeloma who have received previous treatment. The study will assess the safety and effectiveness of different doses and combinations of these drugs compared to a standard combination therapy.
*Third Opinion AI Generated Synopsis
Recurrent Plasma Cell Myeloma and Refractory Plasma Cell Myeloma
Age: 18 +
Genders: All
Phase: Phase 2
This phase II trial looks at how well leflunomide, pomalidomide, and dexamethasone work for treating multiple myeloma that has come back or does not respond to treatment. The combination of these drugs may work better than using pomalidomide and dexamethasone alone, by blocking cancer cell growth, inducing changes in the body's immune system, and stopping the growth and spread of tumor cells.
*Third Opinion AI Generated Synopsis
Recurrent Plasma Cell Myeloma and Refractory Plasma Cell Myeloma
Age: 18 +
Genders: All
Phase: Phase 2
This study is testing how effective isatuximab, carfilzomib, and pomalidomide are in treating patients with multiple myeloma that has relapsed or is not responding to treatment. The three drugs work in different ways to stop cancer cell growth and may help treat this type of cancer.
*Third Opinion AI Generated Synopsis
Multiple Myeloma
Age: 18 +
Genders: All
Phase: Phase 2
This study is evaluating the safety and efficacy of a step-up dosing approach of the study medicine elranatamab in participants with relapsed/refractory multiple myeloma, including different doses and intervals between doses. Participants receive injections under the skin at the study clinic, with the frequency of clinic visits decreasing over time. Participation lasts at least two years.
*Third Opinion AI Generated Synopsis
Smoldering Plasma Cell Myeloma
Age: 18 +
Genders: All
Phase: Phase 2
The trial is examining if leflunomide can delay the symptoms of high-risk smoldering multiple myeloma in both African-American and European-American patients by decreasing the immune response of the body. It's a phase II trial.
*Third Opinion AI Generated Synopsis
Multiple Myeloma and Relapse Multiple Myeloma
Age: 18 +
Genders: All
Phase: Phase 2
Study of Belantamab Mafodotin With Carfilzomib, Pomalidomide, and Dexamethasone in Relapsed Multiple Myeloma
Refractory Multiple Myeloma
Age: 18 +
Genders: All
Phase: Phase 1
This study is testing the safety and effectiveness of combining selinexor, carfilzomib, and dexamethasone to treat multiple myeloma that has returned or is not responsive to other treatments. These drugs work in different ways to stop cancer cells from growing, dividing, or spreading.
*Third Opinion AI Generated Synopsis
Multiple Myeloma
Age: 18 +
Genders: All
Phase: Phase 1
This study is testing a combination of medications including isatuximab, carfilzomib, dexamethasone, and lenalidomide for the treatment of multiple myeloma that has relapsed or is refractory. The hope is that the combination will improve outcomes by inducing changes in the immune system, blocking cancer cell growth, and preventing cancer cells from dividing or spreading.
*Third Opinion AI Generated Synopsis
B-Cell Non-Hodgkin Lymphoma, Histiocytic and Dendritic Cell Neoplasm, Myelodysplastic Syndrome, Previously Treated Myelodysplastic Syndrome, Recurrent Adult Acute Myeloid Leukemia, Recurrent Anaplastic Large Cell Lymphoma, Recurrent Angioimmunoblastic T-Cell Lymphoma, Recurrent Mycosis Fungoides, Recurrent Plasma Cell Myeloma, Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Recurrent T-Cell Non-Hodgkin Lymphoma, Refractory Acute Myeloid Leukemia, Refractory Anaplastic Large Cell Lymphoma, Refractory Angioimmunoblastic T-Cell Lymphoma, Refractory Mycosis Fungoides, Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified, Refractory Plasma Cell Myeloma, Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, and Refractory T-Cell Non-Hodgkin Lymphoma
Age: 18 +
Genders: All
Phase: Phase 1
This clinical trial aims to find the best dosage and potential side effects of VSV-hIFNbeta-NIS virus, which may be able to destroy cancer cells without harming healthy ones. Researchers will test the virus on patients with multiple myeloma, acute myeloid leukemia, or T-cell lymphoma for whom other treatments have been ineffective, and will also measure the effectiveness of ruxolitinib phosphate in stopping tumor growth.
*Third Opinion AI Generated Synopsis
Acute Myeloid Leukemia, Diffuse Large B-Cell Lymphoma, Lymphoma, and Multiple Myeloma
Age: 18 +
Genders: All
Phase: Phase 1
The clinical trial aims to test the safety and effectiveness of an experimental medicine called TTI-622 in patients with relapsed or refractory lymphoma, multiple myeloma, and newly diagnosed acute myeloid leukemia. The study will be conducted in two phases, with the first phase exploring the safety of TTI-622 when administered alone, and the second phase investigating its safety when used with other anticancer medicines.
*Third Opinion AI Generated Synopsis
Multiple Myeloma
Age: 18 +
Genders: All
Phase: Phase 1
The trial will test SEA-BCMA as a treatment for multiple myeloma, determining the appropriate dosage, frequency, and potential side effects through several parts of the study where it is administered alone or with other drugs currently used to treat the disease. The study aims to identify the safety and efficacy of the combination of drugs.
*Third Opinion AI Generated Synopsis
Recurrent Plasma Cell Myeloma
Age: 18 +
Genders: All
Phase: Phase 2
The trial is researching whether daratumumab and hyaluronidase-fihj, a monoclonal antibody, combined with chemotherapy drug pomalidomide is effective in treating multiple myeloma that has returned after stem cell transplant. The combination aims to inhibit cancer cell growth and spread and control the disease in patients.
*Third Opinion AI Generated Synopsis
Recurrent Plasma Cell Myeloma and Refractory Plasma Cell Myeloma
Age: 18 +
Genders: All
Phase: Phase 2
This study aims to test the effectiveness of daratumumab, bortezomib, and dexamethasone followed by daratumumab, ixazomib, and dexamethasone in treating relapsed or refractory multiple myeloma. The treatment uses immunotherapy with monoclonal antibodies and chemotherapy drugs to attack cancer cells and stop their growth.
*Third Opinion AI Generated Synopsis
Plasma Cell Myeloma
Age: 18 +
Genders: All
Phase: Phase 2
A phase II trial is examining how well daratumumab, ixazomib, and dexamethasone, with or without bortezomib help to treat newly diagnosed multiple myeloma patients. Researchers aim to assess whether daratumumab, an immunotherapy monoclonal antibody, can improve the effectiveness of chemotherapy drugs in treating multiple myeloma.
*Third Opinion AI Generated Synopsis
Relapsed and/or Refractory Multiple Myeloma and Relapsed and/or Refractory Non Hodgkin Lymphoma
Age: 18 +
Genders: All
Phase: Phase 1
MT-0169, an investigational drug that recognizes and binds to CD38 receptor found on multiple myeloma and non-Hodgkin lymphoma cancer cells, will be studied in patients with relapsed or refractory disease in a Phase 1 trial. The study will focus on the dose escalation and expansion of MT-0169, which delivers a dose of a modified toxin to kill cancer cells.
*Third Opinion AI Generated Synopsis
Recurrent Plasma Cell Myeloma
Age: 18 - 75
Genders: All
Phase: Phase 2
The trial is testing a new treatment for relapsed multiple myeloma, using a combination of chemotherapy drugs and immunotherapy after donor stem cell transplant, which may help the body's immune system attack cancer cells and reduce the risk of the disease returning. The reduced intensity conditioning regimen may improve patients' survival rates.
*Third Opinion AI Generated Synopsis
Plasma Cell Myeloma
Age: 18 +
Genders: All
Phase: Phase 3
The study aims to confirm the recommended dose of isatuximab combined with lenalidomide and dexamethasone for high-risk smoldering multiple myeloma and demonstrate the clinical benefit of isatuximab in prolonging progression-free survival when compared to lenalidomide and dexamethasone. Secondary objectives include assessing overall response rate, minimal residual disease negativity, time to first-line treatment for multiple myeloma, safety, and tolerability.
*Third Opinion AI Generated Synopsis
Recurrent Histiocytic and Dendritic Cell Neoplasm, Recurrent Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Plasma Cell Myeloma, Refractory Histiocytic and Dendritic Cell Neoplasm, Refractory Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, and Refractory Plasma Cell Myeloma
Age: 18 +
Genders: All
Phase: Phase 1
This trial is testing the safety and optimal dosage of combining choline salicylate and selinexor in patients with non-Hodgkin or Hodgkin lymphoma, multiple myeloma, or histiocytic/dendritic cell neoplasm. Choline salicylate is an anti-inflammatory drug that reduces immune response, while selinexor works by blocking a protein necessary for cancer cell growth. The study aims to provide more information about the effectiveness of this drug combination in treating these types of cancer.
*Third Opinion AI Generated Synopsis
Recurrent Plasma Cell Myeloma and Refractory Plasma Cell Myeloma
Age: 18 +
Genders: All
Phase: Phase 2
This trial is studying the effects of combining selinexor, carfilzomib, daratumumab, and dexamethasone in treating high-risk multiple myeloma patients who have not responded to previous treatments. By blocking certain proteins and inhibiting the proteasome, this combination may be more effective in stopping the growth and spread of cancer cells compared to using carfilzomib, daratumumab, and dexamethasone alone.
*Third Opinion AI Generated Synopsis
Myeloma, Myeloma Multiple, and Refractory Multiple Myeloma
Age: 18 - 74
Genders: All
Phase: Phase 2
The study is testing whether a combination of four drugs (Selinexor, Clarithromycin, Pomalidomide and Dexamethasone) is effective and safe for patients with relapsed/refractory multiple myeloma. The researchers believe that adding Selinexor to the three other drugs will increase the patients’ overall response rate.
*Third Opinion AI Generated Synopsis
Multiple Myeloma
Age: 18 +
Genders: All
Phase: Phase 2
This study aims to evaluate the safety and efficacy of magrolimab in combination with other anticancer therapies for participants with relapsed/refractory multiple myeloma, with a focus on determining the recommended phase 2 dose and measuring the objective response rate.
*Third Opinion AI Generated Synopsis
Plasma Cell Myeloma
Age: 18 +
Genders: All
Phase: Phase 2
This study aims to investigate the safety of long-term use of isatuximab in patients with multiple myeloma who have completed a previous study. Adult patients who have benefitted from isatuximab therapy will be enrolled in this study to continue receiving the treatment.
*Third Opinion AI Generated Synopsis
Recurrent Multiple Myeloma and Refractory Multiple Myeloma
Age: 18 +
Genders: All
Phase: Phase 1
Elotuzumab, CC-92480, and Dexamethasone for the Treatment of Relapsed or Refractory Myeloma After CD38- and BCMA-Targeted Therapies
Relapsed/Refractory Multiple Myeloma
Age: 18 +
Genders: All
Phase: Phase 1
The study aims to test the safety and toxicity of ABBV-453 in adult participants with relapsed/refractory multiple myeloma. Participants will receive oral ABBV-453 tablets and undergo regular medical assessments to check the effect of the treatment.
*Third Opinion AI Generated Synopsis
High-risk Smoldering Multiple Myeloma and Multiple Myeloma
Age: 18 +
Genders: All
Phase: Phase 2
The study aims to investigate if combining daratumumab SC, lenalidomide, bortezomib, and dexamethasone can effectively treat smoldering multiple myeloma and prevent it from developing into active or symptomatic multiple myeloma.
*Third Opinion AI Generated Synopsis
Leukemia, Lymphoma, and Myeloma
Age: 18 +
Genders: All
Phase: Phase 1
A gene transfer research study using special immune cells aims to model a new treatment for the type of cancers known as NHL, Multiple Myeloma (MM) or CLL, that have not gone away after treatment. The gene transfer experiment combines the use of T cells and new antibodies that are chemically created, and researchers found that T cells work better when a certain protein is added to stimulate them, to create cells that will last longer in the body for the patient.
*Third Opinion AI Generated Synopsis
Multiple Myeloma and Osteoporosis
Age: 18 +
Genders: All
Phase: Phase 1
This study aims to find out if romosozumab is a safe and effective treatment for osteoporosis and myeloma-related bone disease in postmenopausal individuals with multiple myeloma by measuring its impact on bone formation and breakdown.
*Third Opinion AI Generated Synopsis
Multiple Myeloma
Age: 18 +
Genders: All
Phase: Phase 1
The study involved testing of P-BCMA-ALLO1 allogeneic T stem cell memory CAR-T cells in several groups of individuals with relapsed or refractory Multiple Myeloma. The study is the first phase of a larger clinical trial involving the CAR-T cells.
*Third Opinion AI Generated Synopsis
Multiple Myeloma
Age: 18 +
Genders: All
Phase: Phase 1
The study aims to investigate whether Trametinib and Dabrafenib could be effective treatments for multiple myeloma.
*Third Opinion AI Generated Synopsis
Multiple Myeloma
Age: 65 +
Genders: All
Phase: Phase 2
This study is looking at the effectiveness of daratumumab in treating multiple myeloma in older adults. It is in the second phase of clinical trials.
*Third Opinion AI Generated Synopsis
Multiple Myeloma
Age: 18 +
Genders: All
Phase: Phase 2
Outpatient Administration of Teclistamab for Multiple Myeloma
Relapsed/Refractory Multiple Myeloma
Age: 18 +
Genders: All
Phase: Phase 2
This study aims to find out how effective Daratumumab, Ixazomib, Pomalidomide and Dexamethasone are in treating Multiple Myeloma.The researchers will measure the response rate of patients to this combination of drugs.
*Third Opinion AI Generated Synopsis
Diffuse Large B-Cell Lymphoma, Diffuse Large B Cell Lymphoma Refractory, Multiple Myeloma in Relapse, and Multiple Myeloma, Refractory
Age: 18 +
Genders: All
Phase: Phase 1
The study is testing a new drug called EZM0414 in people with relapsed/refractory Multiple Myeloma and Diffuse Large B-Cell Lymphoma. The purpose is to determine if the drug is safe, tolerable, and effective, as well as how it is processed within the body.
*Third Opinion AI Generated Synopsis
Relapsed and Refractory Multiple Myeloma
Age: 18 +
Genders: All
Phase: Phase 1
A master protocol has been developed for cell therapy that aims to test its effectiveness in treating relapsed and refractory multiple myeloma. The study includes Phase 1 proof-of-concept trials with long-term safety tracking.
*Third Opinion AI Generated Synopsis
Multiple Myeloma
Age: 18 +
Genders: All
Phase: Phase 2
The study aims to test the effectiveness of a combination of isatuximab, elotuzumab, pomalidomide, and dexamethasone in treating multiple myeloma. The trial includes patients who have relapsed and received at least two prior treatments.
*Third Opinion AI Generated Synopsis
Multiple Myeloma
Age: 18 +
Genders: All
Phase: Phase 2
A Phase II study evaluated the effectiveness of CART-ddBCMA, a CAR-T cell therapy directed towards BCMA, in patients with relapsed or refractory multiple myeloma, a type of cancer. This study aimed to assess if CART-ddBCMA could be a potential treatment option for these patients.
*Third Opinion AI Generated Synopsis
Multiple Myeloma
Age: 18 +
Genders: All
Phase: Phase 1
This trial aims to find the best dose of mephalan for multiple myeloma patients undergoing stem cell transplant by analyzing their blood levels, which may help personalize the treatment and determine who will benefit the most. Mephalan, a chemotherapy drug, can stop the growth of cancer cells in different ways, including killing cells or stopping them from dividing or spreading.
*Third Opinion AI Generated Synopsis
Recurrent Plasma Cell Myeloma and Refractory Plasma Cell Myeloma
Age: 18 +
Genders: All
Phase: Phase 2
This trial tests the effectiveness of a treatment consisting of a monoclonal antibody, a protein blocker, a tumor cell growth inhibitor, and an anti-inflammatory drug in patients with multiple myeloma that has relapsed or is unresponsive to treatment. The treatment aims to kill more cancer cells by interfering with their growth and spread.
*Third Opinion AI Generated Synopsis
Multiple Myeloma
Age: 18 +
Genders: All
Phase: Phase 4
Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)
Plasma Cell Myeloma and Secondary Amyloidosis
Age: 18 - 70
Genders: All
Phase: Phase 2
The study aims to evaluate the effectiveness of daratumumab after a stem cell transplant in treating multiple myeloma by destroying residual cancer cells. Monoclonal antibodies like daratumumab are expected to target and kill cancer cells left behind by chemotherapy.
*Third Opinion AI Generated Synopsis
Hematological Malignancies
Age: 18 +
Genders: All
Phase: Phase 2
This study aims to determine whether talquetamab is effective in treating relapsed or refractory multiple myeloma at the recommended Phase 2 dose(s). It will be evaluated in Part 3 of the study.
*Third Opinion AI Generated Synopsis
Multiple Myeloma, Multiple Myeloma in Relapse, and Refractory Multiple Myeloma
Age: 18 +
Genders: All
Phase: Phase 1
The study aims to test TriPRIL CAR T Cells for treating people with multiple myeloma and evaluate any side effects, along with standard chemotherapy drugs used in the treatment process.
*Third Opinion AI Generated Synopsis
Multiple Myeloma
Age: 18 +
Genders: All
Phase: Phase 1
This clinical research aims to determine if the use of belantamab mafodotin (Blenrep) can prevent the recurrence of multiple myeloma in patients who have undergone an autologous stem cell transplant. The study will also analyze the safety of the drug in the post-transplant period.
*Third Opinion AI Generated Synopsis
Myeloma Multiple
Age: 18 +
Genders: All
Phase: Phase 2
This study aimed to improve the rate of remission in patients with newly diagnosed multiple myeloma who tested positive for minimal residual disease (MRD) by using belantamab mafodotin and lenalidomide as maintenance therapy after a transplant.
*Third Opinion AI Generated Synopsis
Multiple Myeloma
Age: 18 +
Genders: All
Phase: Phase 2
This study aims to assess the effectiveness of budesonide in multiple myeloma patients undergoing stem cell transplant by comparing it to a placebo, with a run-in period involving 20 patients.
*Third Opinion AI Generated Synopsis
Multiple Myeloma
Age: 18 +
Genders: All
Phase: Phase 2
The study is investigating a potential therapy for treating the consequences of Multiple Myeloma combined with renal insufficiency.
*Third Opinion AI Generated Synopsis
Recurrent Plasma Cell Myeloma and Refractory Plasma Cell Myeloma
Age: 18 +
Genders: All
Phase: Phase 2
This study is testing a combination of daratumumab, azacitidine, and dexamethasone in patients with multiple myeloma that has come back or not responded to treatment. Daratumumab, an antibody that attaches to a protein on myeloma cells, is used to prevent the growth of tumors who have high levels of CD38. Meanwhile, chemotherapy and steroids are used to help reduce inflammation and infusion-related reactions, respectively.
*Third Opinion AI Generated Synopsis
Multiple Myeloma
Age: 18 +
Genders: All
Phase: Phase 2
This study aims to compare the usual maintenance therapy for multiple myeloma (lenalidomide) with daratumumab as maintenance therapy to determine which drug provides a better quality of life during treatment for patients who have responded well to initial treatment. The study will measure participants' quality of life using questionnaires to determine whether daratumumab is a better, similar, or worse approach to maintenance therapy.
*Third Opinion AI Generated Synopsis
Multiple Myeloma
Age: 18 - 75
Genders: All
Phase: Phase 2
The study aims to investigate the impact of using daratumumab and lenalidomide, without the use of steroids, on the treatment of multiple myeloma in patients.
*Third Opinion AI Generated Synopsis
Multiple Myeloma
Age: 18 +
Genders: All
Phase: Phase 2
The study looks at different dosing of belantamab mafodotin, a drug for multiple myeloma patients who have relapsed or not responded to treatment before. The goal is to see if changing the dose or schedule can improve the benefits of the treatment while minimizing the risks.
*Third Opinion AI Generated Synopsis
Lymphoma, Multiple Myeloma, Non-Hodgkin Lymphoma, and Relapsed Hodgkin's Disease, Adult
Age: 18 +
Genders: All
Phase: Phase 2
This study will test whether Isatuximab can improve the immune system of patients with multiple myeloma or lymphoma after autologous stem cell transplantation, to better fight their cancer. Participants will be randomly assigned to two groups, with around two-thirds receiving Isatuximab in addition to the standard transplant procedure.
*Third Opinion AI Generated Synopsis
Lymphoma, Multiple Myeloma, and Solid Tumors, Adult
Age: 18 +
Genders: All
Phase: Phase 1
This study aims to evaluate how safe and well-tolerated VP301 is in patients with relapsed or refractory multiple myeloma, lymphoma, or solid tumors, as well as assess its effects on how the drug is absorbed, distributed, metabolized, and eliminated in the body.
*Third Opinion AI Generated Synopsis
Multiple Myeloma, Multiple Myeloma in Relapse, and Refractory Multiple Myeloma
Age: 18 +
Genders: All
Phase: Phase 1
This study will test the combination of ibrutinib, lenalidomide, and dexamethasone in men and women with relapsed or refractory multiple myeloma. It is an open-label, phase 1 clinical trial.
*Third Opinion AI Generated Synopsis
Refractory Multiple Myeloma
Age: 18 +
Genders: All
Phase: Phase 1
This study aims to test whether selinexor is safe and effective in treating multiple myeloma patients who have not responded to a treatment involving lenalidomide, with or without steroids.
*Third Opinion AI Generated Synopsis
Multiple Myeloma
Age: 18 +
Genders: All
Phase: Phase 1
This is a clinical trial testing the combination of disulfiram and copper gluconate in patients with treatment-resistant multiple myeloma. The trial will escalate doses to determine the recommended dose, and then an expansion cohort will further assess the safety and tolerance of the combination.
*Third Opinion AI Generated Synopsis
Multiple Myeloma
Age: 18 +
Genders: All
Phase: Phase 1
This study aims to test the safety and effectiveness of CC-95266 in patients who have multiple myeloma that has come back after treatment or is not responding to treatment.
*Third Opinion AI Generated Synopsis
Multiple Myeloma and Myeloma
Age: 18 +
Genders: All
Phase: Phase 1
The study is testing the safety and effectiveness of FT576 alone and in combination with daratumumab in multiple myeloma patients. The study includes two stages: a dose-escalation stage and an expansion stage.
*Third Opinion AI Generated Synopsis
Multiple Myeloma, Multiple Myeloma in Relapse, Multiple Myeloma, Refractory, Recurrent Plasma Cell Myeloma, and Refractory Plasma Cell Myeloma
Age: 18 +
Genders: All
Phase: Phase 2
This study is testing whether pembrolizumab can help reduce tumors in patients with relapsed or refractory multiple myeloma who did not respond to previous CAR-T therapies. Pembrolizumab works by changing the body's immune system to prevent cancer cells from growing and spreading.
*Third Opinion AI Generated Synopsis
Plasma Cell Myeloma
Age: 18 +
Genders: All
Phase: Phase 2
This study aims to see if pembrolizumab can help patients with multiple myeloma who are not responding to CAR-T cell therapy. Pembrolizumab is a type of immunotherapy that may stimulate the immune system to fight cancer cells.
*Third Opinion AI Generated Synopsis
Recurrent Plasma Cell Myeloma and Refractory Plasma Cell Myeloma
Age: 18 +
Genders: All
Phase: Phase 1
This trial is testing the safety of using MUC1-activated T cells, which are T cells that have been modified to target a protein expressed by multiple myeloma cells, in patients who have relapsed or refractory multiple myeloma. The hope is that the modified T cells will help the patient's immune system to identify and kill cancer cells.
*Third Opinion AI Generated Synopsis
ISS Stage III Plasma Cell Myeloma and Plasma Cell Myeloma
Age: 18 - 80
Genders: All
Phase: Phase 2
This trial tests whether a combination of chemotherapy drugs can improve blood test results in patients with high-risk multiple myeloma by killing, stopping the growth of or preventing the spread of cancer cells. It will also investigate if patients with minimal residual disease will benefit from this drug combination.
*Third Opinion AI Generated Synopsis
Relapsed/Refractory Multiple Myeloma
Age: 18 +
Genders: All
Phase: Phase 1
This study will investigate the safety, effectiveness, and immune response of ISB 1342 in patients with relapsed or refractory multiple myeloma. The researchers will also examine how the drug is processed and how it affects the body.
*Third Opinion AI Generated Synopsis
Cancer and Multiple Myeloma
Age: 18 +
Genders: All
Phase: Phase 2
This study is testing a combination of three drugs - isatuximab, lenalidomide, and dexamethasone - to treat newly diagnosed multiple myeloma. The study will use lower doses to reduce any unwanted side effects, but this combination is not currently approved by the FDA for this use.
*Third Opinion AI Generated Synopsis
Recurrent Plasma Cell Myeloma and Refractory Plasma Cell Myeloma
Age: 18 +
Genders: All
Phase: Phase 1
Researchers are conducting a phase I trial to determine the best dosage and side effects of venetoclax and tocilizumab in treating t(11;14) multiple myeloma that has relapsed or is refractory, wherein venetoclax blocks the protein Bcl-2 to stop cancer cell growth, and tocilizumab may interfere with tumor cell growth and spread while also treating immune therapy side effects. The study's goal is to increase cancer cell death with this combination.
*Third Opinion AI Generated Synopsis
Multiple Myeloma in Relapse
Age: 18 +
Genders: All
Phase: Phase 2
A clinical trial will assess the effectiveness of Selinexor, a selective inhibitor of nuclear export, in combination with other drugs in treating relapsed and refractory multiple myeloma patients that were chosen by their physicians or by ex vivo drug sensitivity testing results. The trial will have three different treatment arms, with Selinexor being combined with either pomalidomide and dexamethasone, daratumumab and dexamethasone, or carfilzomib and dexamethasone.
*Third Opinion AI Generated Synopsis
Relapse/Refractory Multiple Myeloma
Age: 18 +
Genders: All
Phase: Phase 1
The IMMUNICY-1 study aims to examine the effectiveness of the drug CYAD-211 in adults suffering from relapsed or refractory multiple myeloma after a lymphodepletion regimen with fludarabine and/or cyclophosphamide. The study measures the drug's safety, activity, and cell kinetics.
*Third Opinion AI Generated Synopsis
Smoldering Plasma Cell Myeloma
Age: 18 +
Genders: All
Phase: Phase 2
A study is being conducted to determine the effects of iberdomide alone or in combination with dexamethasone on smoldering multiple myeloma patients. The purpose is to induce changes in the immune system and prevent the growth and spread of cancer cells, which may lead to improved time to progression with better tolerance.
*Third Opinion AI Generated Synopsis
Refractory Multiple Myeloma and Relapse Multiple Myeloma
Age: 18 +
Genders: All
Phase: Phase 2
The study is testing whether belantamab mafodotin is safe and effective as maintenance therapy in patients with relapsed and/or refractory multiple myeloma who have received anti-BCMA CAR-T-cell therapy. Patients will receive belantamab mafodotin every 56 days at a dose of 2.5 mg/kg IV.
*Third Opinion AI Generated Synopsis
Multiple Myeloma and Myeloma
Age: 18 +
Genders: All
Phase: Phase 2
The study aims to find out how patients with multiple myeloma respond after receiving eight cycles of treatment with D-KRd (a combination of daratumumab, carfilzomib, lenalidomide, and dexamethasone). It focuses on determining the response rate to this treatment.
*Third Opinion AI Generated Synopsis
Refractory Multiple Myeloma and Relapsed Multiple Myeloma
Age: 18 +
Genders: All
Phase: Phase 1
This study aims to find out the highest dose of ION251 that can be tolerated by patients who have relapsed or refractory multiple myeloma and to recommend a suitable dose for Phase 2 trials.
*Third Opinion AI Generated Synopsis
Multiple Myeloma
Age: 18 +
Genders: All
Phase: Phase 3
The study will compare two different treatments (KRD and VRD) for patients who have recently been diagnosed with multiple myeloma. The goal is to determine which treatment is more effective.
*Third Opinion AI Generated Synopsis
Multiple Myeloma
Age: 18 +
Genders: All
Phase: Phase 1
The study aims to evaluate the safety and effectiveness of belantamab mafodotin as a treatment for Relapsed/Refractory Multiple Myeloma in participants with and without liver impairment. The focus is on assessing the drug's pharmacokinetics, safety, and tolerability.
*Third Opinion AI Generated Synopsis
Multiple Myeloma
Age: 18 +
Genders: All
Phase: Phase 1
Researchers are conducting a phase Ib study to determine the safety and effectiveness of isatuximab, bortezomib, and dexamethasone in newly diagnosed multiple myeloma patients with severe renal impairment or dialysis-dependent end-stage renal disease. Patients with renal impairment have limited treatment options, and this study aims to provide data on the efficacy and tolerability of this therapy.
*Third Opinion AI Generated Synopsis
Multiple Myeloma
Age: 18 +
Genders: All
Phase: Phase 1
This is a clinical trial where the drug STI-1492 is given to people with multiple myeloma who have not responded to previous treatments. The drug is administered intravenously in increasing amounts to determine the best dosage.
*Third Opinion AI Generated Synopsis
Multiple Myeloma
Age: 18 +
Genders: All
Phase: Phase 3
This study aims to determine if elranatamab alone is more effective than lenalidomide alone as a treatment for newly diagnosed multiple myeloma after stem cell transplant. The study will last for about five years and participants will receive either elranatamab injections at the clinic or take lenalidomide at home.
*Third Opinion AI Generated Synopsis
Relapsed or Refractory Acute Myeloid Leukemia and Relapsed or Refractory Multiple Myeloma
Age: 18 - 85
Genders: All
Phase: Phase 1
AMG 176 has been found to be safe and tolerable for patients with relapsed or refractory multiple myeloma and acute myeloid leukemia.
*Third Opinion AI Generated Synopsis
Multiple Myeloma
Age: 18 +
Genders: All
Phase: Phase 3
This is a Phase 3 clinical trial that will compare the effectiveness of bb2121 with standard treatments for people with relapsed and refractory multiple myeloma. The study aims to enroll around 381 participants, with roughly 254 receiving Treatment Arm A and 127 receiving Treatment Arm B.
*Third Opinion AI Generated Synopsis
Multiple Myeloma
Age: 18 +
Genders: All
Phase: Phase 2
This study compares the effectiveness of daratumumab subcutaneous in combination with carfilzomib and dexamethasone versus carfilzomib and dexamethasone alone in participants with relapsed refractory multiple myeloma who have previously been exposed to daratumumab, to evaluate the possibility of daratumumab retreatment. The focus is on evaluating the rate of very good partial response or better.
*Third Opinion AI Generated Synopsis
Relapsed/Refractory Multiple Myeloma
Age: 18 +
Genders: All
Phase: Phase 1
The UNIVERSAL study will evaluate the safety and effectiveness of ALLO-715 along with or without Nirogacestat in treating adults who have multiple myeloma and have relapsed or have not responded to other treatments. The study will also assess the immune response and growth of cells in the patients.
*Third Opinion AI Generated Synopsis
Relapsed/Refractory Multiple Myeloma
Age: 18 - 64
Genders: All
Phase: Phase 1
This study is testing a new treatment called UCART for patients with blood cancer. The aim is to test its safety and effectiveness in treating Relapsed or Refractory Multiple Myeloma and to determine the maximum dose that can be given safely.
*Third Opinion AI Generated Synopsis
Relapsed, Refractory Multiple Myeloma
Age: 18 +
Genders: All
Phase: Phase 2
The RAPA-201-RRMM study is a clinical trial that investigates the use of autologous T cells in adults with relapsed and refractory multiple myeloma who have undergone at least three prior treatments. It is an open-label, single-arm, non-randomised multicentre phase II study.
*Third Opinion AI Generated Synopsis
Multiple Myeloma
Age: 18 - 75
Genders: All
Phase: Phase 2
The study aims to determine the safety and effectiveness of KRD or KRD+DARA in controlling multiple myeloma compared to the current standard treatment, VRD. The goal is to find a better treatment option.
*Third Opinion AI Generated Synopsis
Plasma Cell Myeloma
Age: 18 +
Genders: All
Phase: Phase 1
In a phase I trial, researchers are testing the safety and best dose of a radioimmunotherapy drug called 211At-OKT10-B10, which targets cancer cells and delivers a radioactive substance to kill them, together with chemotherapy drug melphalan before a stem cell transplant in multiple myeloma patients in the hopes of killing more cancer cells.
*Third Opinion AI Generated Synopsis
Multiple Myeloma
Age: 18 +
Genders: All
Phase: Phase 2
The study aims to find the recommended dose and clinical impact of elranatamab when used in combination with other anti-cancer therapies for treating multiple myeloma patients.
*Third Opinion AI Generated Synopsis
Multiple Myeloma
Age: 18 - 75
Genders: All
Phase: Phase 2
The study will measure the time taken for white blood cell counts to return to normal in MM patients who get plinabulin and pegfilgrastim post AHCT. They will be compared with patients receiving pegfilgrastim alone.
*Third Opinion AI Generated Synopsis
Relapsed or Refractory Multiple Myeloma
Age: 18 +
Genders: All
Phase: Phase 1
This study aims to determine the safe and effective dose of ORIC-533, as well as its activity against multiple myeloma in patients who have no more treatment options available.
*Third Opinion AI Generated Synopsis
Multiple Myeloma
Age: 18 +
Genders: All
Phase: Phase 3
This study aims to investigate if iberdomide maintenance therapy is more effective than lenalidomide maintenance therapy after autologous stem cell transplantation in individuals with newly diagnosed multiple myeloma.
*Third Opinion AI Generated Synopsis
Recurrent Plasma Cell Myeloma and Refractory Plasma Cell Myeloma
Age: 18 +
Genders: All
Phase: Phase 2
This trial is studying whether a combination of drugs including ixazomib, dexamethasone, and/or lenalidomide is more effective in treating multiple myeloma that has returned or is resistant to treatment. The study is specifically looking at patients with a certain gene rearrangement called NFKB2.
*Third Opinion AI Generated Synopsis
Multiple Myeloma
Age: 18 +
Genders: All
Phase: Phase 1
This is a study where the drug cevostamab is given to patients with relapsed or refractory multiple myeloma through an IV infusion. The study aims to test the safety and effectiveness of different doses of cevostamab.
*Third Opinion AI Generated Synopsis
Relapsed/Refractory Multiple Myeloma
Age: 18 +
Genders: All
Phase: Phase 1
The study aims to evaluate the safety and tolerability of AMG 701, which will be done in two phases. In the first phase, the primary focus is to identify the recommended dose for AMG 701 and gather safety data for both AMG 701 on its own and in combination with other drugs. The second phase will focus on expanding the study to gain more information on the effectiveness and safety of AMG 701 monotherapy.
*Third Opinion AI Generated Synopsis
Multiple Myeloma
Age: 18 +
Genders: All
Phase: Phase 1
The study CC-93269-MM-001 is a clinical trial testing the safety and effectiveness of CC-93269 in people with relapsed and refractory multiple myeloma. The trial consists of dose escalation and expansion phases to evaluate the drug's tolerability and potential benefits.
*Third Opinion AI Generated Synopsis
Multiple Myeloma
Age: 18 - 70
Genders: All
Phase: Phase 2
This study aims to compare the effectiveness of Melphalan and BEAM treatment in Multiple Myeloma patients. The study is deemed ethical because BEAM has been previously studied for safety and toxicity, and early retrospective data suggests BEAM may be effective in MM.
*Third Opinion AI Generated Synopsis
Multiple Myeloma
Age: 18 - 79
Genders: All
Phase: Phase 3
The study aims to compare the effectiveness of daratumumab and lenalidomide together versus lenalidomide alone in treating newly diagnosed multiple myeloma patients who are positive for minimal residual disease (MRD) after high-dose therapy and autologous stem cell transplant. The study will focus on determining the conversion rate to MRD negativity using next generation sequencing techniques.
*Third Opinion AI Generated Synopsis
Multiple Myeloma
Age: 18 +
Genders: All
Phase: Phase 1
The CC-99712-MM-001 study is testing the safety and effectiveness of CC-99712 either alone or in combination with BMS-986405 in patients with relapsed and refractory multiple myeloma. The study has two parts: Part A is focused on determining the maximum tolerated dose of CC-99712 in monotherapy or combination, while Part B will evaluate the safety and efficacy of CC-99712 at or below the maximum tolerated dose in selected expansion cohorts.
*Third Opinion AI Generated Synopsis
B-Cell Lymphoma, Multiple Myeloma, and Non-Hodgkin Lymphoma
Age: 18 +
Genders: All
Phase: Phase 1
This is a study to test the safety and effectiveness of a drug called tiragolumab, either on its own or in combination with other drugs, in people with relapsed or refractory multiple myeloma or non-Hodgkin lymphoma. The study will evaluate how the drug is processed by the body, how well it works, and any side effects.
*Third Opinion AI Generated Synopsis
Multiple Myeloma
Age: 18 +
Genders: All
Phase: Phase 1
The study will test the safety, effectiveness, and recommended dosage of a drug called belantamab mafodotin when used in combination with other drugs to treat newly diagnosed multiple myeloma. Participants will receive a combination of drugs on a specific schedule and will be monitored for safety after completing the treatment.
*Third Opinion AI Generated Synopsis
Multiple Myeloma (MM)
Age: 18 - 99
Genders: All
Phase: Phase 1
The study aimed to find a safe and well-tolerated dose of WVT078, alone or with WHG626, for patients with relapsed or refractory Multiple Myeloma through an open-label, phase I dose finding study.
*Third Opinion AI Generated Synopsis
Multiple Myeloma, Refractory Multiple Myeloma, and Relapse Multiple Myeloma
Age: 18 - 75
Genders: All
Phase: Phase 2
This study will test a new treatment for relapsed/refractory multiple myeloma using daratumumab in combination with clarithromycin/pomalidomide/dexamethasone until progressive disease or unacceptable toxicity occurs, with the hypothesis that this combination will yield higher Very Good Partial Response rates than the historical pomalidomide/dexamethasone treatment.
*Third Opinion AI Generated Synopsis
Multiple Myeloma
Age: 18 +
Genders: All
Phase: Phase 1
This study will test the safety and effectiveness of genetically modified T cells in treating multiple myeloma. The modified cells will target a specific protein called B-cell Maturation Antigen (BCMA) and will be used as a standalone treatment for patients who have relapsed or are resistant to other treatments.
*Third Opinion AI Generated Synopsis
Multiple Myeloma
Age: 18 +
Genders: All
Phase: Phase 1
This study aims to evaluate the safety and effectiveness of belantamab mafodotin, an anti-cancer drug, in patients with multiple myeloma who have renal impairment. The study will be conducted in two parts, with participants receiving the drug at a dose of either 2.5mg/kg or 1.9mg/kg every three weeks until disease progression or other endpoints occur.
*Third Opinion AI Generated Synopsis
Multiple Myeloma
Age: 18 +
Genders: All
Phase: Phase 3
The study will compare the effectiveness and safety of belantamab mafodotin combined with pomalidomide and dexamethasone to a combination of pomalidomide, bortezomib, and dexamethasone in patients with relapsed/refractory multiple myeloma.
*Third Opinion AI Generated Synopsis
Multiple Myeloma
Age: 18 +
Genders: All
Phase: Phase 2
This study will examine the response rate of patients with multiple myeloma receiving selinexor in combination with carfilzomib, daratumumab, or pomalidomide. Patients will be assigned to the groups based on their current treatment and will continue treatment until disease progression, death, toxicity, or withdrawal.
*Third Opinion AI Generated Synopsis
Myeloma
Age: 18 +
Genders: All
Phase: Phase 2
This study is testing a drug called belantamab mafodotin in patients with multiple myeloma who have undergone stem cell transplantation, to see if it is safe and effective in combination with standard maintenance treatment. The aim is to compare its efficacy to historical data.
*Third Opinion AI Generated Synopsis
Acute Myeloid Leukemia (AML), Multiple Myeloma (MM), and Non-Hodgkin Lymphoma (NHL)
Age: 18 +
Genders: All
Phase: Phase 1
The study aims to discover safe doses and schedules of VOB560 and MIK665 for patients with Non-Hodgkin lymphoma, Multiple Myeloma, or Acute Myeloid Leukemia, and assess whether the combination can benefit such patients by blocking the functions of proteins that protect tumor cells from cell death. Preclinical data shows that treatment with VOB560 and MIK665 together has strong anti-tumor activity.
*Third Opinion AI Generated Synopsis
Multiple Myeloma
Age: 18 +
Genders: All
Phase: Phase 1
The study will test the safety and effectiveness of cevostamab, administered alone or in combination with other drugs, via IV infusion in patients with relapsed or refractory multiple myeloma. Pharmacokinetic and pharmacodynamic parameters will also be evaluated.
*Third Opinion AI Generated Synopsis
Multiple Myeloma
Age: 18 +
Genders: All
Phase: Phase 3
This study aims to compare the effectiveness of a treatment called VRd followed by either cilta-cel or Rd in people with newly diagnosed multiple myeloma who will not undergo a stem cell transplant as their first treatment, specifically looking at how long the disease stays in remission.
*Third Opinion AI Generated Synopsis
Multiple Myeloma
Age: 18 +
Genders: All
Phase: Phase 1
CC-92328 will be tested in a Phase 1 clinical study to evaluate its safety, tolerability, and early clinical activity as a single-agent treatment for relapsed and/or refractory multiple myeloma. The study will consist of two parts, a dose escalation phase, and a dose expansion phase.
*Third Opinion AI Generated Synopsis
Multiple Myeloma
Age: 18 +
Genders: All
Phase: Phase 3
This study aims to compare the effectiveness and safety of two different treatments for relapsed or refractory multiple myeloma. One treatment includes iberdomide, dexamethasone and daratumumab, while the other includes daratumumab, bortezomib, and dexamethasone.
*Third Opinion AI Generated Synopsis
Myeloma
Age: 18 +
Genders: All
Phase: Phase 1
This study aims to test the safety and recommended dose of Belantamab Mafodotin in patients with high-risk smoldering multiple myeloma. It will have two parts - dose-finding and dose-expansion - and will enroll up to 30 patients.
*Third Opinion AI Generated Synopsis
Bladder Cancer, Breast Cancer, Carcinoma of Unknown Primary, Esophageal Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Gastric Cancer, Gastric Junction Adenocarcinoma, Head and Neck Cancer, Malignant Melanoma, Small Cell and Non-small Cell Lung Cancer, Solid Tumor, Squamous Cell Carcinoma of Larynx, Squamous Cell Carcinoma of Nasopharynx, Squamous Cell Carcinoma of Oral Cavity, Squamous Cell Carcinoma of Other Specified Sites of Skin, and Triple Negative Breast Cancer
Age: 18 +
Genders: All
Phase: Phase 2
The study aims to evaluate the use of RAPA-201, a checkpoint-deficient polyclonal T cell therapy platform for solid tumors, manufactured ex vivo from autologous CD4+ and CD8+ T cells using a steady-state apheresis, and endowed with resistance to temsirolimus and Th1/Tc1 polarization. When used in combination with the carboplatin and paclitaxel regimen, the safety and efficacy of RAPA-201 in patients with advanced metastatic, recurrent, and unresectable solid tumors that have recurred or relapsed after prior immune therapy will be assessed to determine a response rate.
*Third Opinion AI Generated Synopsis
Multiple Myeloma
Age: 18 +
Genders: All
Phase: Phase 2
This study aims to test the safety and effectiveness of a new CAR-T cell therapy called PHE885 in treating relapsed and refractory multiple myeloma patients. The therapy will be administered as a stand-alone treatment.
*Third Opinion AI Generated Synopsis
Multiple Myeloma
Age: 18 - 75
Genders: All
Phase: Phase 2
The study aims to determine if iberdomide can be a safe and effective maintenance therapy for individuals with Multiple Myeloma who have undergone an Autologous Hematopoietic Stem Cell Transplant and have previously received lenalidomide therapy.
*Third Opinion AI Generated Synopsis
Recurrent Plasma Cell Myeloma and Refractory Plasma Cell Myeloma
Age: 18 +
Genders: All
Phase: Phase 1
This clinical trial is testing the safety and effectiveness of a combination of three treatments (daratumumab, 111In-DOTA-daratumumab, and 225Ac-DOTA-daratumumab) for multiple myeloma that does not respond to treatment or has come back. The treatments work by interfering with cancer cell growth and delivering targeted radiation to kill more cancer cells.
*Third Opinion AI Generated Synopsis
Multiple Myeloma
Age: 18 +
Genders: All
Phase: Phase 2
This study aims to investigate whether the quality of T cells used to produce a therapy called ide-cel affects its ability to prevent the recurrence of multiple myeloma in patients who have previously received a hematopoietic cell transplant for the disease. The focus is on determining whether ide-cel's efficacy varies based on the composition of T cells used in its creation.
*Third Opinion AI Generated Synopsis
Relapsed or Refractory Multiple Myeloma
Age: 18 +
Genders: All
Phase: Phase 3
This study aims to compare the effectiveness and safety of CC-92480, bortezomib, and dexamethasone with pomalidomide, bortezomib, and dexamethasone in patients with relapsed or refractory multiple myeloma who have undergone 1 to 3 prior treatment lines and experienced lenalidomide exposure.
*Third Opinion AI Generated Synopsis
Multiple Myeloma
Age: 18 +
Genders: All
Phase: Phase 1
The study aims to determine if giving a combination of two drugs, belantamab mafodotin and nirogacestat, is safe and effective in treating people with relapsed or refractory multiple myeloma. The study will test different doses of belantamab mafodotin to find the safest dose to administer alongside nirogacestat and will evaluate how the treatment affects the growth of the cancer.
*Third Opinion AI Generated Synopsis
Refractory Multiple Myeloma and Relapsed Multiple Myeloma
Age: 18 +
Genders: All
Phase: Phase 1
The study aims to assess if anti-BCMA CAR T therapy is safe for individuals who have RRMM. This therapy involves modifying the patient's T-cells to attack cancer cells that express the BCMA protein.
*Third Opinion AI Generated Synopsis
Multiple Myeloma, Myeloma, and Myeloma Multiple
Age: 18 +
Genders: All
Phase: Phase 1
This study aims to test the safety of a new orally available drug that can inhibit an enzyme called MMSET in patients with relapsed or refractory multiple myeloma, a type of cancer, by preventing a specific chemical modification in cells.
*Third Opinion AI Generated Synopsis
Multiple Myeloma
Age: 18 +
Genders: All
Phase: Phase 1
This study aims to evaluate the safety and tolerability of combining elranatamab with either carfilzomib and dexamethasone or maplirpacept. Participants will receive the study medications for a period of about 2 years to determine their effectiveness in treating multiple myeloma.
*Third Opinion AI Generated Synopsis
Relapsed/Refractory Multiple Myeloma
Age: 18 +
Genders: All
Phase: Phase 1
This study aims to test a new treatment called CB-011, which uses CAR-T cell therapy to target a specific protein in multiple myeloma. The study will evaluate the safety, dosage, and effectiveness of CB-011 in patients with relapsed or refractory multiple myeloma.
*Third Opinion AI Generated Synopsis
Multiple Myeloma
Age: 18 +
Genders: All
Phase: Phase 3
A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation
B-Cell Non-Hodgkin Lymphoma and Multiple Myeloma
Age: 60 +
Genders: All
Phase: Phase 2
Geriatric Assessment Guided Interventions to Accelerate Functional Recovery After CAR-T Therapy for Patients 60 Years and Older With B-cell Non-Hodgkin Lymphoma or Multiple Myeloma, GOCART Study
Multiple Myeloma
Age: 18 +
Genders: All
Phase: Phase 2
A Study of Talquetamab for People With Multiple Myeloma Who Have Received BCMA CAR T-Cell Therapy
Multiple Myeloma
Age: 18 +
Genders: All
Phase: Phase 1
The study is the first to examine the effects of tasquinimod, an inhibitor of S100A9, in people with multiple myeloma.
*Third Opinion AI Generated Synopsis
Multiple Myeloma
Age: 18 +
Genders: All
Phase: Phase 2
This study aims to investigate the effectiveness of a treatment for multiple myeloma patients who still have residual cancer cells in their bone marrow after a stem cell transplant, regardless of their initial response to treatment. It will be conducted at one medical center and will involve the enrollment of participants.
*Third Opinion AI Generated Synopsis
Myeloma Multiple
Age: 18 +
Genders: All
Phase: Phase 2
The study aims to determine the rate of complete response without any remaining disease after using Descartes-08 to treat high-risk myeloma patients who still have residual disease after induction therapy. It aims to assess minimal residual disease.
*Third Opinion AI Generated Synopsis
Relapsed and Refractory Multiple Myeloma
Age: 18 +
Genders: All
Phase: Phase 2
This research aims to find out if treating patients with translocation 11;14-positive, relapsed/refractory myeloma using a combination of selinexor, venetoclax, and dexamethasone therapy can enhance the effectiveness of anti-cancer treatment.
*Third Opinion AI Generated Synopsis
Hematological Malignancies
Age: 18 +
Genders: All
Phase: Phase 1
The study will test a drug called KPG-818 in combination with dexamethasone in adult subjects with multiple myeloma, and as a monotherapy in subjects with other hematological malignancies. The goal is to determine safe and effective doses for further studies.
*Third Opinion AI Generated Synopsis
Refractory Leukemia, Refractory Solid Tumors, Relapsed Leukemia, and Relapsed Solid Tumors
Age: 6 - 29
Genders: All
Phase: Phase 1
A study is being conducted to determine the safety and maximum tolerated dose of carfilzomib when used in combination with cyclophosphamide and etoposide for treating pediatric patients with relapsed/refractory solid tumors or leukemia, as carfilzomib is FDA approved for adults with multiple myeloma but not for children.
*Third Opinion AI Generated Synopsis
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Biphenotypic Leukemia, Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Acute Myeloid Leukemia With Variant MLL Translocations, B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, Chemotherapy-Related Leukemia, Chronic Myelomonocytic Leukemia, Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, ISS Stage III Plasma Cell Myeloma, ISS Stage II Plasma Cell Myeloma, Myelodysplastic/Myeloproliferative Neoplasm, Myelodysplastic Syndrome, Myelodysplastic Syndrome With Excess Blasts, Myelodysplastic Syndrome With Gene Mutation, Previously Treated Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Recurrent Adult Acute Myeloid Leukemia, Recurrent Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Refractory Acute Lymphoblastic Leukemia, Refractory Adult Acute Lymphoblastic Leukemia, Secondary Acute Myeloid Leukemia, and Therapy-Related Myelodysplastic Syndrome
Age: 15 - 80
Genders: All
Phase: Phase 2
This clinical trial tests personalized natural killer (NK) cell therapy for patients with certain types of cancer after chemotherapy and umbilical cord blood transplant. The therapy uses NK cells to kill remaining tumor cells and potentially reduce the risk of complications after transplant.
*Third Opinion AI Generated Synopsis
Smoldering Multiple Myeloma
Age: 18 +
Genders: All
Phase: Phase 1
A study is investigating the use of a targeted therapy involving lenalidomide, citarinostat, and PVX-410 as a potential treatment for Smoldering Multiple Myeloma.
*Third Opinion AI Generated Synopsis
Multiple Myeloma
Age: 18 +
Genders: All
Phase: Phase 2
The study aims to test the safety and effectiveness of venetoclax combined with Kd in treating patients who have relapsed or refractory multiple myeloma and received up to three prior therapies. Part 4 of the study is currently accepting participants.
*Third Opinion AI Generated Synopsis
Central Nervous System Lymphoma, Chronic Lymphocytic Leukemia, Diffuse Large B Cell Lymphoma, Lymphoplasmacytic Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Multiple Myeloma, Small Lymphocytic Lymphoma, and Waldenstrom Macroglobulinemia
Age: 18 +
Genders: All
Phase: Phase 2
The study assesses the effectiveness of iopofosine I 131 on patients with select B-cell malignancies who have received previous standard therapy, with Part A focusing on multiple types of cancers and Part B specifically looking at patients with WM who have already undergone two or more treatments.
*Third Opinion AI Generated Synopsis
Multiple Myeloma
Age: 18 +
Genders: All
Phase: Phase 1
Researchers are conducting a study to determine if combining ruxolitinib, steroids, and lenalidomide is safe and effective in treating multiple myeloma patients who are experiencing disease progression. The study is open-label and multicenter, and it is in phase 1.
*Third Opinion AI Generated Synopsis
Hematological Malignancies
Age: 18 +
Genders: All
Phase: Phase 1
This study aims to determine the safe dose and schedule for Talquetamab and further assess its safety in participants. The study is divided into two parts: dose escalation and dose expansion.
*Third Opinion AI Generated Synopsis
Multiple Myeloma
Age: 18 +
Genders: All
Phase: Phase 3
This study aims to compare the length of time participants with t(11;14)-positive multiple myeloma live without disease progression when treated with venetoclax and dexamethasone, versus when treated with pomalidomide and dexamethasone.
*Third Opinion AI Generated Synopsis
Multiple Myeloma
Age: 18 +
Genders: All
Phase: Phase 1
The study is testing the safety and effectiveness of a combination of low dose melphalan and high dose ascorbate acid in patients with multiple myeloma who have already relapsed or become resistant to previous treatments. It is a Phase I clinical trial.
*Third Opinion AI Generated Synopsis
Newly Diagnosed Multiple Myeloma
Age: 18 - 100
Genders: All
Phase: Phase 2
The study is testing the effectiveness and safety of ixazomib alone and in combination with lenalidomide as maintenance therapy for multiple myeloma patients who have had a partial response or better after receiving a certain front-line therapy. The study is randomized and Phase 2.
*Third Opinion AI Generated Synopsis
Multiple Myeloma
Age: 18 +
Genders: All
Phase: Phase 1
This study involves testing increasing doses of Carfilzomib, combined with other medications, in a small group of patients. The aim is to determine the safest and most effective dose.
*Third Opinion AI Generated Synopsis
Newly Diagnosed Multiple Myeloma
Age: 70 +
Genders: All
Phase: Phase 2
Elderly people with newly diagnosed multiple myeloma who are unfit for transplant will receive a combination of daratumumab, bortezomib, revlimid, and dexamethasone till disease progression, drug toxicity or other reasons, and their condition will be monitored for adverse events, laboratory abnormalities, and clinical response.
*Third Opinion AI Generated Synopsis
Multiple Myeloma
Age: 18 +
Genders: All
Phase: Phase 1
The study aims to find the appropriate doses for various treatment combinations and determine their safety for patients. It focuses on daratumumab plus talquetamab, teclistamab plus daratumumab with or without pomalidomide.
*Third Opinion AI Generated Synopsis
Multiple Myeloma
Age: 18 +
Genders: All
Phase: Phase 2
This study aims to assess the rate of minimal residual disease negativity in patients who are treated with JNJ-68284528.
*Third Opinion AI Generated Synopsis
Multiple Myeloma
Age: 18 +
Genders: All
Phase: Phase 2
The study will test if using a combination of drugs called DaraRd followed by another called DRVd can result in more patients achieving minimal residual disease (MRD)-negative status. Only patients with positive MRD status after the first treatment will receive the second treatment, and the duration of therapy will vary for each patient based on individual factors.
*Third Opinion AI Generated Synopsis
Multiple Myeloma, Multiple Myeloma in Relapse, Multiple Myeloma of Bone, and Multiple Myeloma With Failed Remission
Age: 18 - 100
Genders: All
Phase: Phase 1
A study is being conducted to evaluate the safety and effectiveness of HPN217, a new drug, in patients suffering from relapsed or refractory multiple myeloma. The study is in its Phase 1 and is open-label, and will examine the drug's pharmacokinetics, tolerability and safety.
*Third Opinion AI Generated Synopsis
Multiple Myeloma
Age: 18 +
Genders: All
Phase: Phase 2
This study is testing the safety and effectiveness of a treatment, and is open-label (meaning participants know what treatment they are receiving) with a safety lead-in phase.
*Third Opinion AI Generated Synopsis
Autologous Hematopoietic Stem Cell Transplant
Age: 18 +
Genders: All
Phase: Phase 2
Certain blood cancers are more common in veterans due to exposure to Agent Orange and other factors, and treatments like hematologic transplantation can cause negative long-term effects like deconditioning and poor quality of life. While exercise has been shown to help mitigate these effects, a new study is testing the use of neuromuscular electrical stimulation as an alternative exercise strategy to improve physical function and quality of life after HCT.
*Third Opinion AI Generated Synopsis
Neoplasm Malignant
Age: 18 +
Genders: All
Phase: Phase 1
This study aims to find the highest safe dose of SAR442257 for patients with relapsed and refractory multiple myeloma and non-Hodgkin lymphoma, and also to evaluate its safety, pharmacokinetics, immunogenicity, and potential effectiveness against tumors. Once the maximum tolerated dose is determined, a recommended Phase 2 dose will be suggested.
*Third Opinion AI Generated Synopsis
Multiple Myeloma
Age: 18 +
Genders: All
Phase: Phase 2
This study is testing a new combination of drugs to treat newly diagnosed multiple myeloma in patients who are suitable for a stem cell transplant. The drugs being tested are Carfilzomib, Isatuximab, Lenalidomide, and Dexamethasone.
*Third Opinion AI Generated Synopsis
Multiple Myeloma
Age: 18 +
Genders: All
Phase: Phase 3
This study aims to better understand the corneal events seen in some patients with relapsed/refractory multiple myeloma who have been treated with belantamab mafodotin. A sample of tissue from the cornea will be obtained from approximately 25 participants to undergo pathologic examination and composition analysis, regardless of whether they are actively receiving treatment.
*Third Opinion AI Generated Synopsis
Hematological Malignancies
Age: 18 +
Genders: All
Phase: Phase 2
This study aims to determine the effectiveness of teclistamab at a specific dosage in treating a particular condition.
*Third Opinion AI Generated Synopsis
Multiple Myeloma
Age: 18 +
Genders: All
Phase: Phase 1
This study aims to test the safety and effectiveness of RO7425781, a new treatment for people diagnosed with relapsed or refractory multiple myeloma. The study has two parts and it will include participants who have not responded to standard-of-care treatments or are unable to tolerate them.
*Third Opinion AI Generated Synopsis
Plasma Cell Myeloma, RISS Stage II Plasma Cell Myeloma, and RISS Stage I Plasma Cell Myeloma
Age: 18 +
Genders: All
Phase: Phase 3
The trial is comparing a four drug combination to a three drug combination in the treatment of cancer. Adding a drug called bortezomib to the combination may be more effective in shrinking or preventing the cancer from returning.
*Third Opinion AI Generated Synopsis
Monoclonal Gammopathy
Age: 18 +
Genders: All
Phase: Phase 2
This study aims to investigate whether Isatuximab can improve kidney function in patients with MGRS. Although approved by the FDA to treat multiple myeloma, Isatuximab is considered investigational for MGRS treatment in this study.
*Third Opinion AI Generated Synopsis
Acute Myeloid Leukemia, AML, Adult, Multiple Myeloma, and Myeloma
Age: 18 +
Genders: All
Phase: Phase 1
The study will test the safety and appropriate dosage of FT538 as a treatment for acute myeloid leukemia and multiple myeloma, both as a single treatment and in combination with monoclonal antibodies. There will be a stage where dosages are gradually increased, followed by a wider study.
*Third Opinion AI Generated Synopsis
Multiple Myeloma
Age: 18 - 75
Genders: All
Phase: Phase 1
This study aims to test the safety and effectiveness of infusing a combination of CIML NK cells, KP1237, and low dose IL-2 in newly diagnosed multiple myeloma patients who have minimal residual disease before receiving a stem cell transplant. The study is open-label and conducted at a single center.
*Third Opinion AI Generated Synopsis
Autologous Stem Cell Transplant, Multiple Myeloma, and Newly Diagnosed Multiple Myeloma (NDMM)
Age: 75 +
Genders: All
Phase: Phase 2
The study is evaluating if isatuximab combined with usual treatments is safe and useful for newly diagnosed multiple myeloma patients.
*Third Opinion AI Generated Synopsis
Multiple Myeloma
Age: 18 +
Genders: All
Phase: Phase 2
The study aims to examine how safe and effective daratumumab is when used along with Pomalidomide, Dexamethasone, and All-Transretinoic Acid (ATRA) for medical treatment.
*Third Opinion AI Generated Synopsis
Multiple Myeloma
Age: 18 +
Genders: All
Phase: Phase 1
The study aims to evaluate the safety and tolerability of teclistamab in various combination regimens and determine the best dose for these regimens.
*Third Opinion AI Generated Synopsis
Multiple Myeloma
Age: 18 +
Genders: All
Phase: Phase 2
This study aims to determine if minimal residual disease detection through next-generation sequencing can delay autologous hematopoietic stem cell transplantation in patients newly diagnosed with multiple myeloma in phase II clinical trials. The goal is to assess whether this technique is a viable alternative treatment option to traditional AHCT.
*Third Opinion AI Generated Synopsis
Multiple Myeloma
Age: 18 +
Genders: All
Phase: Phase 1
This study is aimed at testing the safety, efficacy, pharmacokinetics and antitumor potential of NMS-03597812 in adult patients with RRMM who have either exhausted standard treatment options that are expected to provide meaningful clinical benefit or for whom standard therapy is considered unsuitable. The study is non-randomized, open-label and multi-center.
*Third Opinion AI Generated Synopsis
Multiple Myeloma
Age: 18 +
Genders: All
Phase: Phase 3
The trial will study the effectiveness and safety of SPd versus EloPd in patients with multiple myeloma who have previously received 1 to 4 anti-MM treatments and an IMiD, PI, and anti-CD38 mAb, with a focus on their HR-QoL impact. It is a randomized, open-label multicenter phase 3 trial.
*Third Opinion AI Generated Synopsis
Multiple Myeloma
Age: 18 - 71
Genders: All
Phase: Phase 2
The study aims to evaluate the effectiveness of bb2121, an anti-B Cell Maturation Antigen (BCMA) chimeric antigen receptor (CAR) T-cell, in improving post-treatment responses in patients with multiple myeloma who have undergone autologous hematopoietic cell transplant. It is a Phase II clinical trial conducted across multiple centers.
*Third Opinion AI Generated Synopsis
Multiple Myeloma
Age: 18 +
Genders: All
Phase: Phase 1
This study aims to understand if talquetamab can be safely administered in various combination regimens and to determine the appropriate doses for these combinations. It focuses on understanding the safety and tolerability of the drug in different doses and combinations.
*Third Opinion AI Generated Synopsis
Multiple Myeloma
Age: 18 +
Genders: All
Phase: Phase 3
The study aims to compare the effectiveness of Tec-Dara with other drugs in treating multiple myeloma and evaluate the safety and efficacy of an alternate dosing schedule for Tec-Dara. Part 1 compares Tec-Dara with DPd and DVd, and Part 2 evaluates the pharmacokinetics and safety of Tec-Dara with an alternative dosing schedule.
*Third Opinion AI Generated Synopsis
Multiple Myeloma
Age: 18 +
Genders: All
Phase: Phase 2
The study aims to test whether iberdomide is safe and effective as a maintenance therapy for patients who have undergone ASCT. The results will determine if a larger phase 3 study comparing iberdomide to lenalidomide as maintenance therapy is feasible.
*Third Opinion AI Generated Synopsis
Multiple Myeloma
Age: 18 +
Genders: All
Phase: Phase 1
This study aims to determine the likelihood of Minimal Residual Disease (MRD)-negative multiple myeloma patients progressing after stopping post-autologous stem cell transplant (ASCT) maintenance therapy. It is a pilot study to identify potential risks associated with the cessation of maintenance therapy.
*Third Opinion AI Generated Synopsis
Malignant Plasma Cell Neoplasm, Multiple Myeloma, and Plasma Cell Neoplasm
Age: 18 +
Genders: All
Phase: Phase 2
This study will test the safety and effectiveness of salvage radiation treatment after BCMA CAR-T therapy in people with relapsed and refractory multiple myeloma who have active disease. The primary goals are to determine the objective response rate and duration of response among responders.
*Third Opinion AI Generated Synopsis
Relapsed/ Refractory Multiple Myeloma
Age: 18 +
Genders: All
Phase: Phase 1
The study aims to determine safe doses of a PD-1 inhibitor with talquetamab or teclistamab and assess the safety and tolerance of combining them.
*Third Opinion AI Generated Synopsis
Multiple Myeloma
Age: 18 +
Genders: All
Phase: Phase 2
This study aims to determine the effectiveness of isatuximab and lenalidomide as maintenance treatment for patients who test positive for minimal residual disease (MRD) after receiving Autologous Stem Cell Transplant (ASCT). The purpose is to see if this combination therapy can help improve the outcomes and prevent relapse in these patients.
*Third Opinion AI Generated Synopsis
Multiple Myeloma
Age: 18 +
Genders: All
Phase: Phase 2
The study aims to determine whether cilta-cel, which has deviated from its usual specifications, is effective and safe for use.
*Third Opinion AI Generated Synopsis
Multiple Myeloma, Refractory Multiple Myeloma, and Relapse Multiple Myeloma
Age: 18 +
Genders: All
Phase: Phase 1
Participants' T cells will be turned into study therapies MCARH109 and MCARH125. Participants will get either MCARH125 by itself or MCARH125 combined with MCARH109.
*Third Opinion AI Generated Synopsis
Acute Myeloid Leukemia (AML) and Multiple Myeloma (MM)
Age: 18 +
Genders: All
Phase: Phase 1
This study aims to assess the safety and feasibility of using CART-38 cells, a type of T cells modified with anti-CD38 receptors, in patients with Acute Myeloid Leukemia and Multiple Myeloma. The study will evaluate the potential benefits of this treatment for these types of cancer.
*Third Opinion AI Generated Synopsis
Relapsed or Refractory Multiple Myeloma
Age: 18 +
Genders: All
Phase: Phase 3
This study aims to compare the effectiveness of two combinations of talquetamab subcutaneously with daratumumab and pomalidomide, and with only daratumumab, respectively, with the combination of daratumumab, pomalidomide, and dexamethasone (DPd).
*Third Opinion AI Generated Synopsis
Relapsed/ Refractory Multiple Myeloma
Age: 18 +
Genders: All
Phase: Phase 3
This study aims to determine whether talquetamab or belantamab mafodotin is more effective in terms of overall response rate or progression-free survival.
*Third Opinion AI Generated Synopsis
Multiple Myeloma
Age: 18 +
Genders: All
Phase: Phase 3
This study aims to analyze the effectiveness of adding teclistamab to the treatment regimen of daratumumab and lenalidomide, and compare it with the standard treatment of daratumumab, lenalidomide, and dexamethasone for multiple myeloma.
*Third Opinion AI Generated Synopsis
Relapsed or Refractory Multiple Myeloma
Age: 18 +
Genders: All
Phase: Phase 3
The study aims to compare the effectiveness of CC-92480 with carfilzomib and dexamethasone (480Kd) against carfilzomib and dexamethasone (Kd) in the treatment of RRMM. The purpose is to find out which treatment is more effective.
*Third Opinion AI Generated Synopsis
Multiple Myeloma
Age: 18 +
Genders: All
Phase: Phase 1
This study aims to investigate the possible side effects of combining modakafusp alfa with other therapies and determine the optimal dosage of combination therapy. Participants will receive increasing doses of modakafusp alfa through a vein until the highest dose without harmful side effects is identified.
*Third Opinion AI Generated Synopsis
Multiple Myeloma
Age: 18 +
Genders: All
Phase: Phase 2
This is a study investigating the safety and effectiveness of combining GPC-100 with propranolol, with or without G-CSF, in approximately 40 patients. Patients will be randomly assigned to one of two treatment arms and will receive propranolol twice daily for a specified duration.
*Third Opinion AI Generated Synopsis
Relapsed or Refractory Multiple Myeloma
Age: 18 +
Genders: All
Phase: Phase 3
This study aims to determine if teclistamab is as effective as PVd/Kd for a specific purpose.
*Third Opinion AI Generated Synopsis
Multiple Myeloma
Age: 18 - 70
Genders: All
Phase: Phase 2
Post-Transplant Maintenance Therapy With Isatuximab Plus Lenalidomide for High-Risk Multiple Myeloma Patients
Multiple Myeloma
Age: 18 +
Genders: All
Phase: Phase 1
This study is being conducted to test the safety and effectiveness of a drug called IGM-2644 in patients with relapsed and/or refractory multiple myeloma. The study will last around 60 months and will enroll participants in different groups to determine the optimal dose of the drug.
*Third Opinion AI Generated Synopsis
Relapsed or Refractory Multiple Myeloma
Age: 18 +
Genders: All
Phase: Phase 1
A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)
Myeloma
Age: 18 +
Genders: All
Phase: Phase 1
Phase I/II Trial of Cord Blood-Derived NK Cells Genetically Engineered With NY-ESO-1 TCR/IL-15 Cell Receptor for Relapsed/Refractory Multiple Myeloma
Monoclonal Gammopathy of Renal Significance and Multiple Myeloma
Age: 18 +
Genders: All
Phase: Phase 2
A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS)
Multiple Myeloma
Age: 18 +
Genders: All
Phase: Phase 3
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)